News

The FDA announced a policy shift for COVID-19 vaccine approvals to focus on Americans considered high-risk of contracting the ...
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
The U.S. Food and Drug Administration on Tuesday said it plans to require new clinical trials for approval of annual COVID-19 ...
The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual COVID-19 boosters for ...
The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...
The change marks a shift in the Food and Drug Administration’s policy on approving COVID-19 vaccines, which the new ...
In the NEJM article, the FDA notes that covid booster uptake has been low in the US, with less than a quarter of people ...
The FDA said moving forward, it will adopt a framework requiring proof that a vaccine can generate antibodies in people over ...
The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 ...
The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans — a move that will limit ...